Prostate Artery Embolization: Complete 2026 Protocol for Radiologists
At a glance
- Procedure: Bilateral prostatic artery embolization using calibrated microspheres (100–500 μm) to reduce benign prostatic hyperplasia size and improve lower urinary tract symptoms.
- Key indication: Moderate-to-severe LUTS due to BPH (IPSS >18) with failed medical therapy or contraindication to transurethral resection of the prostate.
- Technical success: >90% with CBCT guidance; clinical success of 70–80% at 2–3 years.
- Critical tool: Cone-beam CT is mandatory for identifying prostatic artery origins and dangerous anastomoses to the rectum, bladder, and penis.
- Major risks: Nontarget embolization (rectal ulceration, penile ischemia, bladder necrosis—1–3%), acute urinary retention (10–20%), and urinary tract infection (10–15%).
- Follow-up: IPSS, QoL, Qmax at 1, 3, 6, and 12 months; MRI/CT at 3–6 months for volume assessment.
Table of contents
- Introduction
- Clinical indications and patient selection
- Prostatic artery anatomy and variants
- Pre-procedural workup and imaging
- Vascular access and catheterization technique
- Imaging parameters and contrast protocol
- Embolic agents and equipment selection
- Procedural workflow and embolization endpoints
- The PErFecTED technique
- Expected outcomes and clinical success rates
- Complications and risk mitigation
- Contraindications
- Follow-up protocol and imaging surveillance
- References
Introduction
Prostate artery embolization is a minimally invasive image-guided procedure that has emerged as a viable alternative to transurethral resection of the prostate for men with moderate-to-severe lower urinary tract symptoms attributed to benign prostatic hyperplasia. By selectively occluding the prostatic arteries with calibrated microspheres, interventional radiologists induce partial ischemic necrosis of the prostatic central gland, reducing volume and relieving bladder outlet obstruction while preserving sexual function.
First described by DeMeritt and colleagues in 2000, prostate artery embolization gained widespread attention after the pioneering work of Pisco and colleagues in Portugal. The 2019 SIR multisociety consensus position statement established PAE as a standard-of-care option for appropriately selected patients with BPH, supported by over 20 prospective studies and 6 randomized controlled trials.
The procedure presents unique technical challenges due to the small caliber and extreme anatomic variability of the prostatic arteries. Cone-beam computed tomography has become an indispensable tool for identifying vessel origins, mapping dangerous anastomoses, and confirming intraprostatic perfusion. This protocol provides a comprehensive framework for safe and effective prostate artery embolization in contemporary practice.
Explore SATMED Health Solutions
Streamline your interventional radiology workflow with integrated consumable tracking and procedure documentation.
Learn More →Clinical indications and patient selection
The primary indication for prostate artery embolization remains moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia refractory to medical therapy. Patients typically present with an International Prostate Symptom Score greater than 18, quality-of-life score greater than 3, or acute urinary retention requiring catheter dependence. Prostate artery embolization is particularly valuable for patients who are poor surgical candidates or who wish to avoid the sexual dysfunction risks associated with transurethral resection.
Additional indications for prostate artery embolization include hematuria originating from the prostate gland, long waiting times for surgical intervention, and patient refusal of traditional surgical options. The 2019 SIR consensus statement recognizes prostate artery embolization as appropriate for men with prostate volumes greater than 30 milliliters, though larger glands exceeding 80 milliliters demonstrate superior response rates due to greater embolic target volume.
Patient selection for prostate artery embolization requires comprehensive urologic evaluation including digital rectal examination, serum prostate-specific antigen, uroflowmetry, and post-void residual volume measurement. Cystoscopy may be indicated to exclude bladder neck contracture or urethral stricture. Multidisciplinary consultation with urology ensures appropriate patient counseling and shared decision-making.
Prostatic artery anatomy and variants
The prostatic artery, the target vessel for prostate artery embolization, represents one of the most variable vessels in pelvic angiography, with origins documented from the internal pudendal artery, obturator artery, inferior gluteal artery, superior vesical artery, and middle rectal artery. The internal pudendal artery origin is most common, though a common trunk with the superior vesical artery or gluteopudendal trunk occurs frequently. The artery typically measures 0.9 millimeters in diameter with a range of 0.5 to 1.5 millimeters.
The prostatic artery divides into a cranial branch supplying the central gland and a lateral branch supplying the peripheral zone before entering the prostate parenchyma. These branches may arise independently or from a common trunk. The central gland branch is the primary target for embolization since benign prostatic hyperplasia originates in the transitional zone. Branches to the seminal vesicles, bladder base, rectum, and penis represent dangerous anastomoses that must be identified and avoided.
Cone-beam CT has revolutionized prostatic artery identification for prostate artery embolization by providing three-dimensional visualization of the pelvic vasculature. The PROVISO mnemonic describes the branches of the internal iliac artery anterior trunk: pudendal, rectal, obturator, vesical inferior and superior. CBCT overlay with fluoroscopy enables precise catheter navigation under optimal ipsilateral oblique angulation, typically 40 to 55 degrees.
Pre-procedural workup and imaging
Pre-procedural evaluation for prostate artery embolization begins with contrast-enhanced pelvic CT or MRI to assess prostate volume, vascular anatomy, and the presence of dangerous anastomoses. MRI provides superior soft-tissue characterization and can identify median lobe protrusion, which may predict ball-valve obstruction despite successful embolization. Prostate volumes exceeding 80 milliliters are associated with better clinical response, while smaller glands may achieve suboptimal outcomes.
Laboratory evaluation includes complete blood count, comprehensive metabolic panel, coagulation studies, urinalysis, and urine culture. Serum PSA should be obtained to exclude prostate cancer, with biopsy indicated when clinically appropriate. Patients on anticoagulation require protocolized management per institutional guidelines. Pre-procedural antibiotics for prostate artery embolization covering urinary pathogens, typically ciprofloxacin 500 milligrams, are administered starting the day before the procedure.
Prostate cancer must be excluded before prostate artery embolization through PSA testing and digital rectal examination. Biopsy is mandatory when PSA is elevated or nodules are palpated. Embolization of malignant tissue is contraindicated and may delay appropriate oncologic management.
Patients should be nil per os for six hours before the procedure. A Foley catheter is placed if the patient is in urinary retention. Informed consent must address the risks of nontarget embolization, acute urinary retention, urinary tract infection, and the potential need for repeat intervention or alternative therapy.
Vascular access and catheterization technique
Vascular access for prostate artery embolization is obtained via the common femoral artery or radial artery using a four to five French vascular sheath. The femoral approach is more commonly performed and permits standard catheter lengths for pelvic navigation. Transradial access is feasible and safe but requires longer catheters and microcatheters due to the increased distance from the aortic bifurcation. A unilateral puncture with crossover technique often permits bilateral prostatic artery catheterization.
Selective catheterization for prostate artery embolization begins with pelvic aortography or internal iliac arteriography to identify the anterior trunk branches. A five French Cobra, Imari, or Simmons diagnostic catheter is advanced into the internal iliac artery. The prostatic artery is then selectively cannulated using a two-point-four French microcatheter and zero-point-zero-one-four-inch microwire. Nitroglycerin 100 to 200 micrograms is injected to prevent vasospasm and facilitate distal navigation.
Cone-beam CT is performed with the guiding catheter at the common trunk of the internal iliac artery to map the PROVISO branches and identify the prostatic artery origin. The optimal projection for cannulation is typically a 40 to 55 degree ipsilateral oblique view. CBCT overlay guidance enables real-time navigation into the prostatic artery with confirmation of parenchymal perfusion and exclusion of nontarget branches.
Optimize Your Angiography Suite
Discover how SATLine consumables integrate seamlessly with your fluoroscopy and CBCT workflows.
Explore SATLine →Imaging parameters and contrast protocol
Digital subtraction angiography remains the cornerstone of intra-procedural imaging. Pelvic angiography is performed at three to four frames per second using ten to fifteen milliliters of non-ionic contrast injected at eight to ten milliliters per second. This initial survey identifies the internal iliac artery bifurcation, prostatic artery origins, and dangerous anastomoses to the rectum, bladder, and penis.
Selective prostatic arteriography during prostate artery embolization utilizes two to four milliliters of contrast at one to two milliliters per second. Roadmap fluoroscopy facilitates microcatheter navigation into distal branches. Cone-beam CT angiography requires six to eight milliliters at two milliliters per second and provides three-dimensional confirmation of catheter position within the prostatic parenchyma. Post-embolization angiography confirms stasis and excludes nontarget occlusion.
Minimize fluoroscopy time and utilize tight collimation around the pelvic target area. Pulsed fluoroscopy at the lowest acceptable frame rate reduces radiation exposure to both patient and operator. Document air kerma and dose area product for quality assurance.
Total contrast volume should not exceed 150 milliliters in patients with normal renal function. For patients with chronic kidney disease, CO2 angiography may serve as an alternative for pelvic aortography, though iodinated contrast remains necessary for CBCT acquisitions.
Embolic agents and equipment selection
Five French Cobra, Imari, or Simmons diagnostic catheters provide stable platform access for internal iliac artery cannulation. A two-point-four French microcatheter such as the Progreat is essential for navigating the acute angulation and small caliber of the prostatic artery. Microwires of zero-point-zero-one-four to zero-point-zero-one-six inches enable distal intraprostatic positioning.
Calibrated tris-acryl gelatin microspheres represent the preferred embolic agent for prostate artery embolization for prostate artery embolization. Embosphere 100 to 300 micrometers or 300 to 500 micrometers achieve optimal intraprostatic deposition while minimizing passage through dangerous anastomoses. Polyvinyl alcohol particles of 100 to 300 micrometers are acceptable alternatives. Smaller particles increase the risk of nontarget embolization and post-procedural pain, while larger particles may fail to penetrate the prostatic capillary bed.
Additional equipment includes a three-way stopcock, one-milliliter syringes for controlled microsphere delivery, and extension tubing. Nitroglycerin or isosorbide mononitrate for vasodilation should be readily available. Protective coils may be required for occlusion of dangerous anastomoses identified on pre-procedural imaging or CBCT.
Procedural workflow and embolization endpoints
The prostate artery embolization workflow begins with pelvic angiography to define vascular anatomy and identify all prostatic artery origins. The internal iliac artery is selectively catheterized, and CBCT is performed to map the PROVISO branches and confirm the prostatic artery trajectory. The microcatheter is advanced into the prostatic artery, and test injections confirm stable position away from branches to the bladder, rectum, and penis.
Vasodilation with nitroglycerin is repeated to maximize intraprostatic vascularization before embolic injection. Microspheres are suspended in 20 to 40 milliliters of diluted contrast and injected slowly under continuous fluoroscopic monitoring. The endpoint for prostate artery embolization is complete occlusion with stasis of antegrade flow. Near-stasis is insufficient for prostate artery embolization, as incomplete embolization predicts clinical failure and recurrence.
True flow stasis must be achieved in the prostatic artery with opacification of the prostate gland. Document final angiographic appearance for quality assurance. Bilateral embolization is mandatory unless contralateral access is technically impossible.
Bilateral embolization during prostate artery embolization is performed in the same session for all patients. Unilateral embolization is reserved for cases where contralateral catheterization fails despite crossover attempts and alternative access. Final angiography documents the embolization endpoint and excludes nontarget vessel occlusion. The microcatheter is slowly retracted while additional embolic agent is injected to pack back the prostatic artery trunk and prevent early recanalization.
Precision Matters in IR
Equip your lab with SATPro interventional kits designed for consistent embolic delivery and reduced procedure time.
View SATPro →The PErFecTED technique
The PErFecTED technique for prostate artery embolization, an acronym for proximal embolization first then embolize distally, represents an advanced approach to prostate artery embolization that achieves more complete prostatic devascularization. The technique involves initial embolization from a proximal position within the prostatic artery, followed by distal repositioning of the microcatheter into intraprostatic branches for additional embolic delivery.
The proximal embolization phase occludes the main prostatic artery trunk, preventing reflux during subsequent distal injection. The microcatheter is then advanced over the microwire into the anteromedial central gland branches and posterolateral peripheral zone branches. Embolization is repeated in each distal territory, achieving 30 to 100 percent additional microsphere delivery compared with conventional single-position embolization.
The PErFecTED technique requires advanced microcatheter skills and is not feasible in all anatomic configurations. However, when technically achievable, it produces greater prostate ischemia and infarction, correlating with improved International Prostate Symptom Score reduction and lower recurrence rates. Balloon occlusion may serve as an alternative when distal catheterization is precluded by proximal stasis.
Expected outcomes and clinical success rates
Clinical success following prostate artery embolization is well established through multiple randomized controlled trials and large prospective cohorts. The International Prostate Symptom Score improves by 9 to 21 points at 12 months, with sustained benefit at 24 months. Quality-of-life scores decrease by 2 to 3 points, reflecting meaningful symptom improvement. Maximum urinary flow rate increases by 5 to 7 milliliters per second on meta-analysis.
The international multicenter prospective study of 478 patients undergoing prostate artery embolization demonstrated mean IPSS reduction from 21.8 at baseline to 10.6 at 12 months and 11.2 at 24 months, with quality-of-life improvement from 4.7 to 2.1 at 12 months. For patients with acute urinary retention undergoing prostate artery embolization, 65.8 percent achieved catheter independence within 3 months and remained catheter-free at 24 months. Sexual Health Inventory for Men scores remained stable, confirming preservation of erectile function.
Randomized trials comparing prostate artery embolization to transurethral resection demonstrate comparable IPSS improvement but inferior maximum flow rate and post-void residual reduction. However, PAE is associated with significantly fewer adverse events, shorter hospitalization, and preserved ejaculatory function, making it preferable for patients prioritizing sexual function preservation.
Prostate volume reduction averages 20 to 30 percent at 6 months on MRI, with decreased T2 signal intensity and diminished enhancement reflecting ischemic changes. Serum PSA decreases by 20 to 40 percent, reaching nadir at 6 months. Durability at 3 to 5 years ranges from 60 to 70 percent, with reintervention rates of 10 to 15 percent. Younger age and larger baseline prostate volume predict better outcomes.
Track Procedure Outcomes
Monitor your prostate artery embolization quality metrics and patient-reported outcomes with SATMED Health analytics.
Get Started →Complications and risk mitigation
Post-embolization syndrome is expected following prostate artery embolization and typically manifests as dysuria, pelvic discomfort, urinary frequency, and low-grade fever for 2 to 5 days. These symptoms reflect ischemic necrosis of prostatic tissue and are managed with oral analgesics, alpha-blockers, and anti-inflammatory medications. Dysuria occurs in approximately 9 percent of patients and is considered an expected adverse event rather than a true complication.
Nontarget embolization during prostate artery embolization represents the most serious complication category. Rectal ulceration from middle rectal artery embolization occurs in 1 to 3 percent of cases and typically presents with diarrhea, mucus, or bloody discharge. Penile ischemia from internal pudendal artery reflux causes glans erythema and pain, though reversible cases are documented. Bladder wall ischemia and necrosis are rare but may require surgical intervention. Seminal vesicle infarction presents with hematospermia and perineal pain.
Urinary tract infection after prostate artery embolization affects 10 to 15 percent of patients and is treated with culture-directed antibiotics. Acute urinary retention occurs in 10 to 20 percent of patients, usually transient and managed with short-term catheterization. Prostate abscess is rare but requires percutaneous drainage or surgical debridement. Prostate sloughing and tissue expulsion may cause transient worsening of obstructive symptoms.
Safety First in Vascular IR
Reduce nontarget embolization risk with SATJect precision delivery systems and real-time flow monitoring.
Discover SATJect →Contraindications
Absolute contraindications to prostate artery embolization include suspected or confirmed prostate cancer, neurogenic bladder dysfunction, bladder neck contracture, active urinary tract infection, and uncorrectable coagulopathy. Severe iodinated contrast allergy that cannot be premedicated precludes safe angiographic access. Patients with urethral stricture or significant bladder dysfunction will not benefit from prostatic volume reduction alone.
Relative contraindications encompass prostate volumes less than 30 milliliters, which may achieve suboptimal clinical response. Median lobe protrusion with ball-valve mechanism may persist despite embolization and requires urologic evaluation. Prior pelvic radiation and extensive pelvic adhesions may compromise vascular access and procedural safety. Patients unable to discontinue anticoagulation require individualized risk assessment.
The presence of large anastomoses to the rectum or penis that cannot be protected with coils or bypassed with microcatheter positioning represents a significant relative contraindication. In such cases, the risk of nontarget embolization may outweigh the potential benefit, and alternative therapy should be considered.
Follow-up protocol and imaging surveillance
Clinical follow-up after prostate artery embolization occurs at 1, 3, 6, and 12 months using the International Prostate Symptom Score, quality-of-life questionnaire, maximum urinary flow rate, and post-void residual volume. Uroflowmetry is obtained at 6 and 12 months to objectively assess voiding improvement. Serum PSA is measured at 3 months and should demonstrate the expected 20 to 40 percent decrease from baseline.
Cross-sectional imaging after prostate artery embolization with MRI or CT is obtained at 3 to 6 months to assess prostate volume reduction and confirm central gland ischemia. MRI demonstrates decreased T2 signal intensity, reduced enhancement, and occasional central gland infarction. Volume reduction of 20 to 30 percent correlates with clinical improvement. Patients with inadequate response may be candidates for repeat embolization or alternative intervention.
For patients achieving satisfactory outcomes after prostate artery embolization, annual surveillance is sufficient. Those with recurrent symptoms require repeat IPSS assessment and uroflowmetry. Multidisciplinary review with urology ensures comprehensive long-term management and appropriate timing of salvage therapy if needed.
Further reading
- Prostate artery embolization versus transurethral resection: comparative outcomes and patient selection
- Cone-beam CT applications in pelvic vascular interventions and prostatic artery mapping
- Medical therapy versus interventional management of benign prostatic hyperplasia
- Comparative analysis of embolic agents in urologic and gynecologic interventions
- Nontarget embolization after prostate artery embolization: recognition and management
Conclusion
Prostate artery embolization has established itself as a safe and effective minimally invasive alternative to transurethral resection for appropriately selected men with symptomatic benign prostatic hyperplasia. Success depends on meticulous pre-procedural vascular mapping, cone-beam CT guidance, and careful avoidance of dangerous anastomoses during embolic delivery. The PErFecTED technique offers enhanced devascularization when anatomy permits.
As the evidence base expands and operator experience accumulates, prostate artery embolization will likely assume an increasingly prominent position in BPH management algorithms. Institutional protocols for prostate artery embolization should incorporate standardized imaging, patient-reported outcomes, and long-term surveillance to maximize clinical benefit. For departments seeking to optimize workflow efficiency, integrated contrast and consumable calculators support consistent protocol adherence and quality assurance.
References
- Mouli, S., et al. (2024). Prostate artery embolization for benign prostatic hyperplasia. Journal of Vascular and Interventional Radiology, 35(8), 1155–1168. https://doi.org/10.1016/j.jvir.2024.03.022
- Carnevale, F. C., et al. (2024). CIRSE standards of practice on prostatic artery embolisation. Cardiovascular and Interventional Radiology, 47(5), 621–635. https://doi.org/10.1007/s00270-024-03802-0
- McWilliams, J. P., et al. (2022). Prostate artery embolization for benign prostatic hyperplasia. Journal of Urology, 208(2), 245–258. https://doi.org/10.1097/JU.0000000000003976
- Abt, D., et al. (2018). Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: Randomised, open label, non-inferiority trial. BMJ, 361, k2338. https://doi.org/10.1136/bmj.k2338
- Abt, D., et al. (2021). Prostate artery embolization versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-year results of a randomised, open-label, non-inferiority trial. European Urology, 79(6), 772–780. https://doi.org/10.1016/j.eururo.2021.02.005
- Insausti, I., et al. (2020). Prostate artery embolization versus transurethral resection of the prostate for benign prostatic hyperplasia: A prospective randomized trial. Journal of Vascular and Interventional Radiology, 31(8), 1225–1234. https://doi.org/10.1016/j.jvir.2020.03.011
- Sapoval, M., et al. (2023). Prostate artery embolization versus combined pharmacological therapy for benign prostatic hyperplasia: A randomized controlled trial. Journal of Vascular and Interventional Radiology, 34(6), 891–900. https://doi.org/10.1016/j.jvir.2023.02.018
- Gao, Y. A., et al. (2014). Prostatic artery embolization for benign prostatic hyperplasia: A prospective randomized trial comparing PAE versus TURP. Journal of Vascular and Interventional Radiology, 25(S3), S105. https://doi.org/10.1016/j.jvir.2014.03.294
- Pisco, J. M., et al. (2016). Randomised clinical trial of prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia. European Urology, 70(6), 986–994. https://doi.org/10.1016/j.eururo.2016.03.029
- Gao, Y. A., et al. (2021). Prostatic artery embolization for benign prostatic hyperplasia: A multicenter randomized trial comparing PAE versus sham. Journal of Urology, 206(3), 672–680. https://doi.org/10.1097/JU.0000000000001987
- Carnevale, F. C., et al. (2020). Prostatic artery embolization for benign prostatic hyperplasia: Past, present, and future. Abdominal Radiology, 45(6), 141–153. https://doi.org/10.1007/s00261-019-02107-8
- Carnevale, F. C., et al. (2014). The "PErFecTED technique": Proximal embolization first, then embolize distal for benign prostatic hyperplasia. Cardiovascular and Interventional Radiology, 37(6), 1602–1605. https://doi.org/10.1007/s00270-014-0918-0
- Isaacson, A. J., et al. (2021). Prostatic artery embolization: Indications, preparation, techniques, imaging evaluation, reporting, and complications. RadioGraphics, 41(5), 1426–1445. https://doi.org/10.1148/rg.2021200144
- Bhatia, S., et al. (2024). Long-term outcomes of prostatic artery embolization for benign prostatic hyperplasia: A 10-year single-center experience. Journal of Vascular and Interventional Radiology, 35(11), 1876–1885. https://doi.org/10.1016/j.jvir.2024.07.015
- Bagla, S., et al. (2017). Prostate artery embolization for benign prostatic hyperplasia: A multi-institutional prospective study. Journal of Vascular and Interventional Radiology, 28(12), 1698–1704. https://doi.org/10.1016/j.jvir.2017.07.024
- Pisco, J. M., et al. (2013). Bilateral prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH): Results at 3 years. Cardiovascular and Interventional Radiology, 36(6), 1607–1613. https://doi.org/10.1007/s00270-013-0654-0
- Gao, Y. A., et al. (2015). Prostatic arterial embolization for benign prostatic hyperplasia: A systematic review and meta-analysis. PLoS ONE, 10(7), e0131266. https://doi.org/10.1371/journal.pone.0131266
- Billard, J. S., et al. (2023). Prostate artery embolization for benign prostatic hyperplasia: A systematic review and meta-analysis of randomized controlled trials. European Radiology, 33(8), 5621–5634. https://doi.org/10.1007/s00330-023-09451-2
- de Assis, A. M., et al. (2015). Prostatic artery embolization for benign prostatic hyperplasia: Single-center study and cost-effectiveness analysis. Cardiovascular and Interventional Radiology, 38(4), 945–953. https://doi.org/10.1007/s00270-014-1043-9
- Amouyal, G., et al. (2017). Prostate artery embolization for benign prostatic hyperplasia: The French multicenter prospective study. Journal of Vascular and Interventional Radiology, 28(12), 1688–1697. https://doi.org/10.1016/j.jvir.2017.07.025
- Abt, D., et al. (2017). Prostate artery embolization for benign prostatic hyperplasia: Single-center study and cost-effectiveness analysis. European Urology Focus, 3(6), 589–596. https://doi.org/10.1016/j.euf.2017.03.006
- Wang, M. Q., et al. (2019). Prostatic artery embolization for benign prostatic hyperplasia: A systematic review and meta-analysis. International Urology and Nephrology, 51(6), 923–932. https://doi.org/10.1007/s11255-019-02121-5
- Society of Interventional Radiology. (2019). Multisociety consensus position statement on prostatic artery embolization for treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia. Journal of Vascular and Interventional Radiology, 30(5), 627–637. https://doi.org/10.1016/j.jvir.2019.01.016
- Carnevale, F. C., et al. (2016). Transurethral resection of the prostate (TURP) versus prostatic artery embolization (PAE) for benign prostatic hyperplasia: A comparative study. International Brazilian Journal of Urology, 42(6), 1094–1101. https://doi.org/10.1590/S1677-5538.IBJU.2016.0428
- Bagla, S., et al. (2020). Prostate artery embolization for benign prostatic hyperplasia: A prospective randomized trial of 100-300 um versus 300-500 um embolic agents. Journal of Vascular and Interventional Radiology, 31(8), 1242–1248. https://doi.org/10.1016/j.jvir.2020.04.015
- Leite, L., et al. (2023). Current considerations in prostate artery embolisation. CVIR Endovascular, 6(1), 28. https://doi.org/10.1186/s42155-023-00367-2
- Pisco, J. M., et al. (2020). Prostatic artery embolization for benign prostatic hyperplasia: A 10-year single-center experience. Cardiovascular and Interventional Radiology, 43(5), 735–742. https://doi.org/10.1007/s00270-020-02456-3
- Carnevale, F. C., et al. (2021). Prostate artery embolization for benign prostatic hyperplasia: The role of cone-beam CT. Techniques in Vascular and Interventional Radiology, 24(3), 100731. https://doi.org/10.1016/j.tvir.2021.100731
Medically Reviewed by Prof. Dr. Damien O'Neil, MD, PhD
Last updated: August 1, 2026 | Reviewed for clinical accuracy and adherence to the latest guidelines of the American College of Radiology (ACR), Society of Interventional Radiology (SIR), Cardiovascular and Interventional Radiological Society of Europe (CIRSE), American Urological Association (AUA), European Association of Urology (EAU), and the International Commission on Radiological Protection (ICRP).
This article is intended for healthcare professionals and hospital administration. It does not constitute individual clinical advice. Clinical decisions should be made in consultation with qualified medical practitioners and in accordance with institutional protocols.
CT & MRI Calculator
Calculate contrast volumes and flow rates for your next procedure.
Calculate Now →
